Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
Cendrowicz E, Jacob L, Greenwald S, Tamir A, Pecker I, Tabakman R, Ghantous L, Tamir L, Kahn R, Avichzer J, Aronin A, Amsili S, Zorde-Khvalevsky E, Gozlan Y, Vlaming M, Huls G, van Meerten T, Dranitzki ME, Foley-Comer A, Pereg Y, Peled A, Chajut A, Bremer E. Cendrowicz E, et al. Among authors: peled a. J Exp Clin Cancer Res. 2022 Mar 14;41(1):97. doi: 10.1186/s13046-022-02256-x. J Exp Clin Cancer Res. 2022. PMID: 35287686 Free PMC article.
Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers.
Abraham M, Pereg Y, Bulvik B, Klein S, Mishalian I, Wald H, Eizenberg O, Beider K, Nagler A, Golan R, Vainstein A, Aharon A, Galun E, Caraco Y, Or R, Peled A. Abraham M, et al. Among authors: peled a. Clin Cancer Res. 2017 Nov 15;23(22):6790-6801. doi: 10.1158/1078-0432.CCR-16-2919. Epub 2017 Aug 23. Clin Cancer Res. 2017. PMID: 28835380 Clinical Trial.
CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways.
Klein S, Abraham M, Bulvik B, Dery E, Weiss ID, Barashi N, Abramovitch R, Wald H, Harel Y, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, Galun E, Pereg Y, Peled A. Klein S, et al. Among authors: peled a. Cancer Res. 2018 Mar 15;78(6):1471-1483. doi: 10.1158/0008-5472.CAN-17-0454. Epub 2017 Dec 19. Cancer Res. 2018. PMID: 29259008
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. Borthakur G, et al. Among authors: peled a. Cancer. 2021 Apr 15;127(8):1246-1259. doi: 10.1002/cncr.33338. Epub 2020 Dec 3. Cancer. 2021. PMID: 33270904 Free article. Clinical Trial.
Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo.
Rodionov G, Rosenzwaig M, Tzadok MS, Kvint M, Gevir E, Zorde-Khvalevsky E, Peled A, Yarkoni S, Ofer A. Rodionov G, et al. Among authors: peled a. Bone Marrow Transplant. 2022 Aug;57(8):1250-1259. doi: 10.1038/s41409-022-01698-3. Epub 2022 May 10. Bone Marrow Transplant. 2022. PMID: 35538142 Free PMC article.
The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.
Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, Tiomkin L, Ribakovsky L, Riback Y, Ramati Y, Aviel S, Galun E, Shaw HL, Eizenberg O, Hardan I, Shimoni A, Nagler A. Peled A, et al. Clin Cancer Res. 2014 Jan 15;20(2):469-79. doi: 10.1158/1078-0432.CCR-13-1302. Epub 2013 Nov 18. Clin Cancer Res. 2014. PMID: 24246358 Clinical Trial.
321 results